54
Participants
Start Date
June 9, 2017
Primary Completion Date
July 24, 2019
Study Completion Date
October 4, 2019
IMO-2125
IMO-2125 will be administered by intratumoral injection on Days 1, 8, and 15 of Cycle 1 and on Day 1 of each subsequent cycle.
Roswell Park Cancer Institute, Buffalo
UPMC Hillman Cancer Center, Pittsburgh
St. Luke's Hospital, Easton
The Cleveland Clinic Foundation, Cleveland
Rabin Medical Center Beilinson Campus, Petah Tikva
MD Anderson Cancer Center, Houston
Scottsdale Healthcare Hospitals DBA Honor Health, Scottsdale
The University of Arizona Cancer Center, Tucson
University of California San Francisco (UCSF), San Francisco
Rambam Medical Center, Haifa
The Ella Lemelbaum Institute for Immuno-Oncology, Ramat Gan
Hadassah Medical Center, Jerusalem
Lead Sponsor
Idera Pharmaceuticals, Inc.
INDUSTRY